Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain

Erin Johansson,1 Mercedes Nuñez,2 Axel Svedbom,1 Tatiana Dilla,2 Susanne Hartz3 1Access, Commercialisation & Communications, ICON plc, Stockholm, Sweden; 2Health Outcomes and Real World Evidence, Eli Lilly, Madrid, Spain; 3Global Patient Outcomes and Real World Evidence Internatio...

Full description

Bibliographic Details
Main Authors:	Johansson E, Nuñez M, Svedbom A, Dilla T, Hartz S
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-11-01
Series:	ClinicoEconomics and Outcomes Research
Subjects:	Pharmacoeconomics cost-utility biologics IL-17A antagonists
Online Access:	https://www.dovepress.com/cost-effectiveness-of-ixekizumab-versus-secukinumab-in-the-treatment-o-peer-reviewed-article-CEOR

Similar Items

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Sekhon S, et al.
Published: (2017-11-01)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017-03-01)

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
by: Giunta A, et al.
Published: (2017-06-01)

Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
by: Kazemi T, et al.
Published: (2017-04-01)

Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis
by: Andreas Pinter, et al.
Published: (2020-11-01)

Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis – a real life retrospective study
by: Katarzyna Galica, et al.
Published: (2020-07-01)

Secukinumab in the treatment of psoriasis: patient selection and perspectives
by: Yang EJ, et al.
Published: (2018-10-01)

Ixekizumab
by: İlgen Ertam Sağduyu
Published: (2022-04-01)

Secukinumab Therapy in Psoriasis Management
by: Ira Yunita, et al.
Published: (2022-03-01)

Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study
by: Andrea Chiricozzi, et al.
Published: (2020-07-01)

Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)
by: Andrea Chiricozzi, et al.
Published: (2023-12-01)

A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis
by: Lynda Spelman, et al.
Published: (2022-01-01)

Secukinumab
by: Nilgün Atakan
Published: (2022-04-01)

Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study
by: Ramesh M Bhat, et al.
Published: (2017-01-01)

The real-life efficacy and safety of secukinumab therapy (150 and 300 mg) in patients with moderate-to-severe plaque psoriasis: A twelve week, single center, retrospective study
by: İncilay Kalay Yıldızhan, et al.
Published: (2021-09-01)

IL-17A Inhibitor Switching – Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience
by: Shany Sherman, et al.
Published: (2019-05-01)

Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry
by: Martina Kojanova, et al.
Published: (2022-08-01)

Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab
by: A. Egeberg, et al.
Published: (2022-07-01)

Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration
by: Andrea Frustaci, et al.
Published: (2023-06-01)

Treatment of acrodermatitis continua of hallopeau with ixekizumab
by: Austinn C. Miller, et al.
Published: (2021-01-01)

Pyoderma gangrenosum in a patient on ixekizumab
by: Ilana R. Pollack, MSc, et al.
Published: (2021-10-01)

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
by: Jashin J. Wu, et al.
Published: (2020-04-01)

Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study
by: Shany Sherman, et al.
Published: (2020-12-01)

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
by: April Armstrong, et al.
Published: (2019-11-01)

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
by: Talamonti M, et al.
Published: (2023-04-01)

Acrodermatitis continua of Hallopeau successfully treated with secukinumab
by: Riccardo Balestri, et al.
Published: (2018-11-01)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Ren V, et al.
Published: (2013-03-01)

Secukinumab for plaque psoriasis
by: Gonzalo Ordenes-Cavieres, et al.
Published: (2018-11-01)

Invasive Aspergillus infection of middle ear in a patient treated with secukinumab, methotrexate, and corticosteroids for psoriasis and psoriatic arthritis
by: Filip Rob, et al.
Published: (2022-10-01)

Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis
by: April W. Armstrong, et al.
Published: (2017-04-01)

The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
by: Joshua Burshtein, et al.
Published: (2024-02-01)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023-03-01)

No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis
by: Therezia Bokor-Billmann, et al.
Published: (2019-04-01)

Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients)
by: Francisco Javier Melgosa Ramos, et al.
Published: (2023-09-01)

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
by: Ruggiero A, et al.
Published: (2022-06-01)

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
by: Pinter A, et al.
Published: (2019-07-01)

Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)
by: Bruna Lavinas Sayed Picciani, et al.
Published: (2021-06-01)

Role of secukinumab in ankylosing spondylitis with tubercular uveitis
by: Padmamalini Mahendradas, et al.
Published: (2020-01-01)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016-10-01)

IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis
by: Xing Wang, et al.
Published: (2022-01-01)